Trial Profile
A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 22 Feb 2024
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary) ; Bleomycin; Dacarbazine; Doxorubicin; Vinblastine
- Indications Hodgkin's disease
- Focus Registrational; Therapeutic Use
- Acronyms ECHELON-1
- Sponsors Seagen; Takeda Oncology
- 18 Oct 2023 According to Takeda pharma media release, European Commission (EC) approved ADCETRIS (brentuximab vedotin) in combination with doxorubicin, vinblastine and dacarbazine AVD to treat adult patients with previously untreated CD30 Stage III Hodgkin lymphoma.
- 18 Oct 2023 According to Takeda pharma media release, John Radford is lead investigator of this study.
- 14 Jun 2023 According to a Seagen media release, the company announced an update to the U.S. Prescribing Information (PI) for ADCETRIS (brentuximab vedotin) to include six-year overall survival results from this study.